PREVENTING PNEUMOCOCCAL DISEASE IN THE UNITED KINGDOM WITH PNEUMOCOCCAL VACCINES

1 Mayon-White R , editor. The clinical impact of pneumococcal disease and strategies for its prevention. London: The Royal Society of Medicine; 1995.

2 Nuorti J JC Butler Farley MM Cigarette smoking and invasive pneumococcal disease. NEJM 2000; 342:681-9.

3 Mao C M Harper McIntosh K Invasive pneumococcal disease infections in human immunodeficiency virus-infected children. J Infect Dis 1996; 173:870-6.

4 MacFarlane J. The clinical impact of pneumococcal disease. In: Mayon-White RT, editor. The clinical impact of pneumococcal disease and strategies for its prevention. Royal Society of Medicine International Congress and Symposium Series 1995; London Royal Society Medicine: 210:9-17.

5 Kauppinen M E Herva Kujala P The aetiology of community-acquired pneumonia among hospitalised patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172:1330-5.

6 Laurichesse H O Grimaud Waight P Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. Communicable Disease and Public Health 1998; 1:22-7.

7 Breiman R J Spika Navarro V Pneumococcal bacteremia in Charleston County, South Carolina a decade later. Arch Intern Med 1990; 150:1401-5.

8 Teele D J Klein Rosner B Epidemiology of otitis media during the first seven years of life in children in Greater Boston: a prospective, cohort study. J Infect Dis 1989; 160:83-94.

9 Klein J. Otitis media. Clin Infect Dis 1994;19:823-33.

10 Reacher MH A Shah Livermore DM Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320:213-6.

11 Ghaffar F IR Friedland Mccracken GH. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J 1999; 18:638-46.

12 Black S Issues Shinefield H. and challenges: pneumococcal vaccination in pediatrics. Ped Annals 1997; 26:355-60.

13 Greenwood B. The epidemiology of pneumococcal infection in children in the developed world. Phil Trans R Soc Lond B 1999; 354:777-85.

14 Cundell D N Gerard Gerard C Streptococcus pneumoniae anchor to activated human cells by the receptor for plateletactivating factor. Nature 1995; 377:435-8.

15 Gray B M Turner Dillon HJ. Epidemiologic studies of Streptococcus pneumoniae in infants: the effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life. Am J Epidemiol 1982; 116:692-703.

16 Montgomery J D Lehmann Smith T Bacterial colonization of the upper respiratory tract and its association with acute respiratory tract infections in Highland children of Papua New Guinea. Rev Infect Dis 1990; 12(suppl 8):S1006-16.

17 Kellner J A McGeer Cetron MS The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J 1998; 17:279-86.

18Alonso de Velaasco E, Verheul A, Verhoef J Streptococcus pneumoniae: virulence factors, pathogenesis and vaccines. Microbiological Reviews 1995; 59:591-603.

19 Tuomanen EI R Austrian Masure HR. Pathogenesis of pneumococcal infection. NEJM 1995; 332:1280-4.

20 Knecht J G Schiffman Austrian R. Some biological properties of pneumococcus type 37 and the chemistry of its capsular polysaccharide. J Exp Med 1970; 132:475-87.

21Lee C-J, Banks SD, Li JP. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Critical Rev Microbiol 1991; 18:89-114.

22 Austrian R R Douglas Schiffman G Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184-94.

23 Musher D J Groover Rowland J Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and antibody response. Clin Infect Dis 1993; 17: 66-73.

24 Finland M Bacteriological Tilghman R. studies immunological of Streptococcus pneumoniae in infants: the development of type specific antibodies in healthy carriers. J Clin Invest 1936; 15:501-8.

25 Musher D J Groover Reichler M Emergence of antibody of capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. J Infect Dis 1997; 24:441-6.

26 Nielsen S Henrichsen J. Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982–1987. Clin Infect Dis 1992; 15:794-8.

27 Butler J R Breiman Lipman H Serotypes distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171:885-9.

28 Sniadack DH B Schwartz Lipman H Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children – implications for vaccine strategies. Pediatr Infect Dis J 1995; 14:503-10.

29 Hausdorff WP J Bryant Kloek C The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, Part II. Clinical Infectious Diseases 2000; 30:122-40.

30 Hausdorff WP J Bryant Paradiso PR Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, Part I. Clinical Infectious Disease 2000; 30:100-21.

31 Kyaw MH S Clarke Edwards G Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implication for vaccine strategies. Epidemiol Infect 2000; 125:561-72.

32 Hansman D Bullen M. A resistant pneumococcus. Lancet 1967; 1:264-5.

33 Jacobs M H Koornhof Robins-Browne R Emergence of multiply resistant pneumococci. N Eng J Med 1978; 229:735-40.

34 Cole KJ JC Sniffen JP Nadler , editors. Global epidemiology of antibiotic resistance. Program and abstracts from the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Franciso; 1999.

35 Soares S K Kristinsson Musser J Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis 1993; 168:158-63.

36 Klugman K. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3:171-96.

37 Block S C Harrison Hedrick J Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995; 14:751-9.

38 Dagan R P Yagupsky Goldbart A Increasing prevalence of penicillin resistant pneumococcal infections in children in southern Israel: implications for future immunization policies. Pediatr Infect Dis J 1994; 13:782-6.

39 Zenni M S Cheatham Thompson J Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995; 127:533-7.

40 Arnold K R Leggiadro Breiman R Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr 1996; 128:757-64.

41 Dagan R R Melamed Muallem M Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996; 174:1352-5.

42 Appelbaum P. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15:77-83.

43 Marton A M Gulyas Munoz R Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991; 163:542-8.

44Song J-H, Lee NY, Ichiyama S Spread of drug-resistance Streptococcus pneumoniae in Asian countries: Asian network for surveillance of resistant pathogens (ANSORP) study. Clinical Infect Dis 1999; 28:1206-11.

45 Forward KR. The epidemiology of penicillin resistance in Streptococcus pneumoniae. Semin Resp Infect 1999; 14:243-54.

46 Manson EJ Kaplan S. Penicillin-resistant pneumococci in the United States (letter). Pediatr Infect Dis J 1995; 14:1017-8.

47 Hofmann J M Cetron Farley M The prevalence of drugresistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481-6.

48 Hermans P M Sluijter Dejsirilert S Molecular epidemiology of drug-resistant pneumococci: toward an international approach. Micro Drug Resist 1997; 3:243-51.

49 George G. Epidemiology of pneumococcal disease. In: Mayon-White RT, editor. The clinical impact of pneumococcal disease and strategies for its prevention. Royal Society of Medicine 1995 (International Congress and Symposium Series 210):1-5.

50 Butler J R Breiman Campbell J Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-31.

51 Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999; 17:S85-S90.

52 Hutchison BG AD Oxman Shannon HS Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999; 45:2381-93.

53 Sisk JE AJ Moskowitz Whang W Cost-effectiveness of vaccination against pneumococcal bacteraemia among elderly people. JAMA 1997; 278:1333-9.

54 Ament A R Baltussen Duru G The cost effectiveness of pneumococcal vaccination for older people: a study in five western European countries. Clin Infect Dis 2000; 31:444-50.

55Department of Health. Immunisation against infectious disease. London: HMSO; 1996.

56 McDonald P E Friedman Banks A Pneumococcal vaccine campaign based in general practices. BMJ 1997; 314:1094-8.

57 Kyaw M J Nguyen-Van-Tam Pearson J. Family doctor advice is the main determinant of pneumococcal vaccine uptake. J Epidemiol Community Health 1999; 53:589-90.

58 Fedson D. Pneumococcal conjugate vaccination for adults: why it’s important for children. Pediatr Infect Dis J 2000; 19: 183-6.

59 Stein K. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165(suppl):S49-S52.

60 Fine MJ MA Smith Carson C Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trails. Arch Intern Med 1994; 154:2666-77.

61 Watson L. Effectiveness of pneumococcal polysaccharide vaccine: a systematic review and meta-analysis (MSc dissertation). University of Aberdeen; 1999.

62Bandolier. Are pneumococcal vaccine effective? Bandolier 2000; 72:72-4.

63 Bailar J. The promise and problems with meta-analysis. N Engl J Med 1997; 337:559-61.

64 Wang E. Administration of pneumococcal vaccine. In: Canadian Task Force on the periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada; 1994; 386-95.

65Morbidity and Mortality Weekly Report (MMWR). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46:1-24.

66 Clemens J Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials. Reviews of Infectious Diseases 1984; 6:589-600.

67 Fedson DS. Measuring protection: efficacy versus effectiveness. Dev Biol Stand 1998; 195:195-201.

68 Shelly M H Jacoby Riley G Comparison of pneumococcal polysaccharide vaccine and CRM 197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65:242-7.

69 Schneerson R O Barrera Sutton A Preparation, characterization, and immunogenecity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152:361-76.

70 Eskola J Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999; 18:543-51.

71 Watson W. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 2000; 19:331-2.

72 Fedson D D Musher Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: W.B. Saunder Company; 1999; 553-607.

73 Klein DL Ellis RW. Conjugate vaccines against Streptococcus pneumoniae. In: Levine MM, Woodrow GC, Kaper JB et al, editors. New generation vaccines. Second edition. New York: Marcel Dekker Inc; 1997;503-25.

74 Douglas R J Paton Duncan S Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148:131-7.

75 Molrine D G Siber Tarbell N Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin’s disease. Ann Intern Med 1995; 123:828-34.

76 Chan C D Morline Siber G Pneumococcal conjugate vaccine primes for antibody responses to polysacharide pneumococcal vaccine after treatment of Hodgkin’s disease. J Infect Dis 1996; 173:256-8.

77 King JC PE Vink Chang IH Antibody titers eight months after three doses of a 5-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 1998; 16:361-5.

78 Vernacchio L EJ Neufeld MacDonald K Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133:275-8.

79 Sorensen R L Leiva Giangrosso P Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17:685-91.

80 Barnett E S Pelton Cabral H Immune response to pneumococcal conjuagte and polysaccharide vaccines in otitisprone and otitis-free children. Clin Infect Dis 1999; 29:191-2.

81 Black S H Shinefield Fireman B Efficacy, safety and immunogenecity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.

82 Leach A SJ Ceesay Banya WAS Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996; 15:333-9.

83 Powers D E Anderson Lottenbach K Reactogenicity and immunogenicity of a protein conjugated pneumococcal oligosoccharide vaccine in older adults. J Infect Dis 1996; 173:1014-8.

84 Shinefield H S Black Safety Ray P. of immunogenecity heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999; 18:757-63.

85 Obaro S R Adegbola Banya W Carriage of pneumococci after pneumococcal vaccine. Lancet 1996; 348:271-2.

86 Dagan R M Muallem Melamed R Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphteria toxoid. Pediatr Infect Dis J 1997; 16:1060-4.

87 Mbelle N RE Huebner Wasas AD Immunogenecity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180:1171-6.

88 Lieu TA GT Ray Black SB Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283:1460-8.

89 Hueston W A Mainous Brauer N. Predicting cost-benefits before programs are started: looking at conjugate vaccine for invasive pneumococcal infections. J Community Health 2000; 25:23-33.

90 Ahmed F M Steinhoff Rodriguez-Barradas M Effect of human immunodeficiency virus type 1 on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomised trial. J Infect Dis 1996; 173:83-90.

91 Vidarsson G S Sigurdardottir Gudnason T Isotypes and opsonophagocytosis pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998; 66:2866-70.

92 Soininen A I Seppala Nieminen T IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 1999; 17:1889-97.

93 Kaufman P. Pneumonia in old age. Active immunization against pneumonia with pneumococcus polysaccharide: results of a six-year study. Arch Intern Med 1947; 79:518-31.

94 Gaillat J D Zmirou Mallaret MR Essai Clinique du vaccin antipneumococcique chez personnes agees vivant en institution. Rev Epidemiol Sante Publique 1985; 33:437-44.

95 Simberkoff M A Cross Al-lbrahim M Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administrative Cooperative Study. N Engl J Med 1986; 315:1318-27.

96 Koivula I M Sten Makela P. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind populationbased trail. Am J Med 1997; 103:281-90.

97 Ortqvist A J Hedlund Burman A Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in the prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351:399-403.

98 Macleod C R Hodges Heidelberger M Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 82:445-65.

99 Austrian R. Vaccines of pneumococcal capsular polysaccharides and the prevention of pneumococcal pneumonia, in the role of immunological factors in infectious, allergic, and autoimmune processes. In: Basset RJ, editor. The role of immunological factors in infectious allergic and autoimmune processes. New York: Raven Press; 1976; 79-89.

100 Smit P D Oberholzer Hayden-Smith S Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238:2613-6.

101 Riley I P Tarr Andrew M Immunisation with a polyvalent pneumococcal pneumonia. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977; 1:1338-41.

102 Broome C R Facklam Fraser D. Pneumococcal disease after pneumococcal vaccination. An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980; 303:549-52.

103 Shapiro E Clemens J. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infection. Ann Intern Med 1984; 101:325-30.

104 Bolan G C Broome Facklam R Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104:1-6.

105 Forrester H D Jahnigen LaForce F. Inefficacy of pneumococcal vaccine in high-risk population. Am J Med 1987; 83:425-30.

106 Sims R W Steinmann McComville J The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108:653-7.

107 Shapiro E A Berg Austrian R The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Eng J Med 1991; 325:1453-60.

108 Farr B B Johnston Cobb D Preventing pneumococcal bacteraemia in patients at risk. Results of matched casecontrol study. Arch Intern Med 1995; 155:2336-40.

109 Davidson M AJ Parkinson Bulkow L Epidemiology of invasive pneumococcal disease: reply. J Infect Dis 1995;171:1065-6.